Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. The Journal of nutrition vol
It is well-tolerated, extensively studied, and provides a strong foundation before adding more targeted peptides
Theres therefore a strong mechanistic case for providing older adults with extra NAD+
Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
Puglisi R, Tramer F, Panfili E, Micali F, Sandri G, Boitani C